Article Details
Retrieved on: 2022-12-01 21:45:08
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The first-in-human trial of NTX1088, a monoclonal antibody, will test its activity in patients who miss out on anti-PD-1 immunotherapy benefit.
Article found on: www.precisiononcologynews.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here